Danlei Yu

The novel MET inhibitor, HQP8361, possesses single agent activity and enhances therapeutic efficacy of AZD9291 (osimertinib) against AZD9291-resistant NSCLC cells with activated MET.

T. Owonikoko, S. Ramalingam, Shi-Yong Sun, 2020, American journal of cancer research.

Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling

Shi-Yong Sun, Karin A Vallega, Danlei Yu, 2021, Lung Cancer.

The novel MET inhibitor, HQP8361, possesses single agent activity and enhances therapeutic efficacy of osimertinib, against NSCLC cells with acquired resistance to osimertinib due to MET amplification

S. Ramalingam, Shi-Yong Sun, Yiting Li, 2020 .

Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer

Wen-jun Tian, Danlei Yu, Yue Zeng, 2021, Current opinion in oncology.

Nanoparticles for co-delivery of Osimertinib and Selumetinib to Overcome Osimertinib-acquired Resistance in Non-small Cell Lung Cancer.

Shi-Yong Sun, Feng Li, Danlei Yu, 2021, Acta biomaterialia.

Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers

Chen Chen, S. Fan, Chunhong Hu, 2021, Journal for ImmunoTherapy of Cancer.

CPSF6-mediated XBP1 3'UTR shortening attenuates cisplatin-induced ER stress and elevates chemo-resistance in lung adenocarcinoma.

Juan Chen, J. Chen, Kaiwen Zhang, 2023, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib

T. Owonikoko, S. Ramalingam, Shi-Yong Sun, 2021, Oncogene.